HOME >> MEDICINE >> NEWS
Implantable defibrillators cost-effective for preventing sudden death

DALLAS, April 16 In the first study of its kind, an implantable cardioverter defibrillator (ICD), a device used to treat heart rhythm abnormalities, was found to be moderately cost-effective for preventing sudden cardiac death, according to a report in todays rapid access Circulation: Journal of the American Heart Association.

ICDs deliver electrical shocks to the heart to eliminate abnormal rhythms such as ventricular fibrillation or ventricular tachycardia. In the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial, the device was shown to be superior to therapy with antiarrhythmic medications for reducing all causes of death in survivors of ventricular fibrillation (irregular, chaotic heart rhythm that begins in the hearts lower chambers). It was also a better choice for people with ventricular tachycardia (an often serious rapid rhythm originating in the lower chambers) and ejection fractions of 40 percent or less. Ejection fraction is a measure of the hearts pumping ability.

AVID is the first study to prospectively determine the cost-effectiveness of ICDs for secondary prevention in the United States, according to lead author Greg Larsen, M.D, a staff cardiologist at the Portland VA Medical Center and associate professor of medicine at the Oregon Health and Sciences University, Portland, Oregon. The study looked only at treating patients who had had life-threatening arrhythmias and were at risk for another life-threatening event. Researchers compared life gained and costs due to ICD treatment with that of antiarrhythmic drug therapy.

To find out which treatment was more cost-effective, researchers compiled data on charges for initial and repeat hospitalizations, emergency room and day surgery stays, and the costs of antiarrhythmic drugs from 1,008 patients. These included 505 patients with an ICD. Detailed records of all other medical encounters and expenses, including outpatient services and prescription costs, were
'"/>

Contact: Carole Bullock
carole.bullock@heart.org
214-706-1279
American Heart Association
15-Apr-2002


Page: 1 2 3

Related medicine news :

1. Implantable heart defibrillators
2. Statement: Implantable medical identification chip
3. Implantable cardiac defibrillator use significantly lowers heart failure mortality
4. Implantable device pumps up ailing heart
5. Implantable heart device reduces deaths by one-third
6. Implanted defibrillators cut heart patients death risk, some more than others
7. Implanted defibrillators not covered for half of patients who could benefit, study finds
8. More doubts over value of defibrillators
9. One use every seven years makes automated external defibrillators a good buy
10. Benefit of public defibrillators is marginal
11. Health and fitness facilities need defibrillators

Post Your Comments:
(Date:7/28/2014)... WA (PRWEB) July 28, 2014 According to ... Vkool.com, this is a comprehensive fitness guide that teaches men ... per week. , Vkool reveals in its review that ... discover:, Ways to gain the maximum ... to build muscle and avoid fat gain , ...
(Date:7/28/2014)... July 28, 2014 TherapySites, ... health professionals, announced today its affiliation with the ... This new relationship allows TherapySites to continue to extend ... benefits and promotional offers. , “There has been a ... today. With nearly 3 billion Internet users, it ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 CW4K was ... First Lady Michelle Obama and Partnership for a ... as they join the group's DrinkUP effort, ... water, more often. , The seven organizations added ... Nalgene® Outdoor Products, S’well Bottle, Santa Clara Valley Water ...
(Date:7/28/2014)... July 28, 2014 Footwear etc. is ... styles from Mephisto. With shoes, sandals, and boots that ... products continually provide handmade comfort shoes and ... women have come to rely on the superb value, ... Mephisto shoes and sandals contain the highest quality materials ...
(Date:7/28/2014)... Washington, DC (PRWEB) July 28, 2014 ... beyond, many are looking to private exchanges. “Private ... the August 6 webinar from Atlantic Information Services, will ... insurers’ private exchange strategies for the future. , Barbara ... from PwC with extensive experience in the private exchange ...
Breaking Medicine News(10 mins):Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 2Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 3Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 2Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 3Health News:Footwear etc. Highlights Phenomenal Models of Mephisto Shoes 2Health News:Footwear etc. Highlights Phenomenal Models of Mephisto Shoes 3Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2
(Date:7/28/2014)... Germany und LONDON ... , Ziel der Zusammenarbeit sind ... genomischer Daten aus Plasmaproben zur Steuerung von Therapien ... werden kann  Neuer Bluttest basiert auf ... und soll auf Rotor-Gene Q, einer Automationsplattform der ...
(Date:7/28/2014)... and LONDON , July 28, 2014 ... to create and commercialize companion diagnostic using genomic data ...  for non-small cell lung cancer patients  New ... test and is planned to run on Rotor-Gene Q, member of ... enabled by AstraZeneca master framework agreement adds to QIAGEN,s ...
(Date:7/28/2014)... 2014 CTI BioPharma Corp. (CTI) (NASDAQ and ... second quarter 2014 financial results on Monday, August 4, ... Following the announcement, members of the management team will ... and provide a general corporate update at 4:30 p.m. ... be obtained as follows: Monday, August 4 ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2
Cached News: